A renal tumor (RCC) study of this vaccine showed that in vivo administration of this vaccine to mice resulted in a significant reduction in tumor growth and progression, a reduction in the vascular network within tumors, increased infiltration of CD8+ and CD4+ T cells into the TME and expression of beneficial cytokines (IFN-γ, IL-2, TNF-α) and a reduction in the population of suppressor cells (Treg Cd4+Fox3+), confirming the effectiveness of the method (67). Here, CD4 is linked to neoplasm.